Atlas Trials

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Clinical trial NCT04501120 · RECRUITING

Trial details

NCT number
NCT04501120
Sponsor
Ascentage Pharma Group Inc.
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed/Refractory Acute Myeloid LeukaemiaMyeloid Malignancy
Start date
2020-09-28
Primary completion
2028-09-01
Enrollment
682

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.